Real-world utilization and outcomes with dacomitinib first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer among Asian patients – A multi-center chart review - ARIA-A741067

Pfizer Inc0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年12月19日

试验速览

暂无简介。

•1. Adults (aged =18 years) with histology-confirmed advanced NSCLC (TNM stage IIIB-IV);
•2. Presence of any EGFR-activating mutation (exon 19 deletion or exon 21 L858R substitution) or other uncommon EGFR mutations prior to anti-cancer treatment;
•3. Initiating dacomitinib as first-line treatment for advanced NSCLC after confirmation of EGFR-mutation status (ie, no prior treatment with other EGFR TKI or systemic therapy);
•4. Received dacomitinib after the following dates (which mark the marketing authorization date in China, or initiation of the compassionate use program in Malaysia and India)
•Patients from China: 01 July 2019;
•Patients from Malaysia and India: 01 August 2018;
•5. Initiated dacomitinib no later than 20 months before end of data collection (to allow minimum of 20 months follow-up from dacomitinib initiation);
•6. Had at least one follow-up visit after dacomitinib initiation unless there is a documented death in the patient records before a follow-up visit.
•For prospective and mixed patients, there should be evidence of a personally signed and dated informed consent document (ICD) indicating that the patient (or a legally acceptable representative, LAR) has been informed of all pertinent aspects of the study.

•1. Enrolled in any interventional clinical study or trial at time of study inclusion (however, patients enrolled in non-interventional, real world study may still be included).

发起方